BGLC on Nasdaq
BioNexus Gene Lab Corp
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Psychemedics Corporation, Renalytix plc or AMERICAN SHARED HOSPITAL SERVICES, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
14.6%Gross margin2
-39.9%Operating margin2
-40.2%Net margin2
-21.9%Revenue growth, 20252
-34.6%Return on equity2
-$1.9MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
MYMember brought in 79% of the revenue BioNexus Gene Lab Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| MYMember | $7.5M | $5.8M |
| MV | $762.1K | $681.0K |
| LK | $459.0K | $452.6K |
| SGMember | $572.0K | $240.8K |
| ID | $138.3K | $114.9K |
| BD | $123.3K | $106.3K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue85¢$6.3M
- Research and development1¢$50.7K
- Other costs14¢$1.0M
Out of $7.4M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| REVENUE (including $68,104 and $112,556 of revenue from related party for the year ended December 31, 2025 and 2024 respectively) | $7.4M | $9.5M |
| COST OF REVENUE (including $9,503 and $297,736 of cost of revenue from related party for the year ended December 31, 2025 and 2024, respectively) | -$6.3M | -$8.2M |
| GROSS PROFIT | $1.1M | $1.3M |
| Dividend income | $22.1K | $68.1K |
| Interest income | $83.9K | $147.6K |
| Fair value gain on investments in equity securities | $0 | $69.5K |
| Gain on disposal of investments in equity securities | $27.2K | $38.4K |
| Reversal of expected credit losses | $144.8K | $1.7M |
| Gain from foreign exchange | $94.7K | $0 |
| Others | $59.5K | $59.4K |
| TOTAL OTHER INCOME | $432.1K | $2.1M |
| Sales and marketing | -$1.7M | -$2.0M |
| Research and development | -$50.7K | -$47.5K |
| General and administrative (including $4,206 and $1,969 of rental expenses to related party for the year ended December 31, 2025 and 2024, respectively) | -$1.5M | -$1.8M |
| Share-based compensation | -$794.8K | -$141.0K |
| Fair value loss on investments in equity securities | -$94.0K | $0 |
| Provision for expected credit losses | -$271.2K | -$883.5K |
| TOTAL OPERATING EXPENSES | -$4.5M | -$4.9M |
| LOSS FROM OPERATIONS | -$3.0M | -$1.6M |
| FINANCE COSTS | -$19.5K | -$21.1K |
| LOSS BEFORE TAXES | -$3.0M | -$1.6M |
| Deferred tax | $0 | -$12.3K |
| Income tax | $0 | $15.8K |
| Tax expense | $0 | $3.5K |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | -$3.0M | -$1.6M |
| Foreign currency translation gain | $434.3K | $122.3K |
| COMPREHENSIVE LOSS | -$2.6M | -$1.5M |
| Earnings per share - Basic and diluted | -$1.61 | -$0.90 |
| Weighted average number of common stocks outstanding, Basic and Diluted # | 1.9M shares | 1.8M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and bank balances | $2.4M | $1.6M | |
| Fixed deposits placed with financial institutions (including $1,553,322 and $1,490,461 of fixed deposits with original maturities more than 3 months as of December 31, 2025 and December 31, 2024 respectively) | $1.7M | $2.8M | |
| Trade receivables, net of allowance for credit losses of $703,995 and $517,877 as of December 31, 2025 and December 31, 2024 respectively (including $31,420 and $47,272 of trade receivables from related party as of December 31, 2025 and December 31, 2024 respectively) | $505.9K | $1.4M | |
| Other receivables, deposits and prepayments | $81.7K | $203.7K | |
| Other assets | $83.3K | $0 | |
| Tax recoverable | $61.4K | $84.2K | |
| Inventories (including goods in transit of $Nil and $188,797 as of December 31, 2025 and December 31, 2024 respectively) | $676.7K | $1.4M | |
| Total current assets | $5.4M | $7.4M | |
| Operating lease right-of-use assets | $177.7K | $215.2K | $141.5K |
| Property, plant and equipment, net | $1.6M | $1.5M | |
| Investments in equity securities | $2.0M | $1.3M | |
| Total non-current assets | $3.8M | $3.0M | |
| TOTAL ASSETS | $9.3M | $10.4M | |
| Trade payables | $2.3K | $1.5M | |
| Other payables and accrued liabilities | $401.6K | $284.1K | |
| Current portion of operating lease liabilities | $59.1K | $50.8K | |
| Advance payment from customer | $8.4K | $95.9K | |
| Amount owing to directors | $49.5K | $17.2K | |
| Total current liabilities | $521.0K | $2.0M | |
| Non-current portion of operating lease liabilities | $116.9K | $159.7K | |
| Total non-current liability | $116.9K | $159.7K | |
| TOTAL LIABILITIES | $637.9K | $2.1M | |
| As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value; 30,000,000 share authorized and no shares outstanding (on a post-reverse stock split basis)*. | $20.2M | $17.3M | |
| Additional paid in capital | -$5.0M | -$5.0M | |
| Accumulated deficit | -$6.4M | -$3.4M | |
| Accumulated other comprehensive losses | -$120.7K | -$555.0K | |
| TOTAL STOCKHOLDERS' EQUITY | $8.6M | $8.3M | $9.7M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $9.3M | $10.4M | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares outstanding | 2.4M shares | 1.8M shares | |
| Preferred stock, par value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 30.0M shares | 30.0M shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Fixed deposits | $1.6M | $1.5M | |
| Allowances for credit losses in trade receivable | $704.0K | $517.9K | |
| Trade receivables from related parties | $31.4K | $47.3K | |
| Inventories, goods in transit | $0 | $188.8K |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$3.0M | -$1.6M |
| Amortization of right-of-use asset | $56.4K | $49.0K |
| Allowances for expected credit losses | $271.2K | $883.5K |
| Recoveries for expected credit losses | -$144.8K | -$1.7M |
| Bad debts written off | $0 | $6.3K |
| Depreciation of property, plant and equipment | $111.9K | $104.2K |
| Dividend income | -$22.1K | -$68.1K |
| Fair value loss/(gain) on investments in equity securities, net | $94.0K | -$69.5K |
| Loss arising from settlement of supplier contract dispute | $0 | $29.5K |
| Gain on disposal of investments in equity securities | -$27.2K | -$38.4K |
| Loss on lease termination | $0 | $1.4K |
| Impairment on property | $0 | $40.2K |
| Share-based compensation | $794.8K | $141.0K |
| Operating loss before working capital changes | -$1.9M | -$2.2M |
| Inventories | $711.9K | -$250.9K |
| Trade, other receivables and other assets | $782.8K | $147.8K |
| Trade and other payables | -$1.4M | $204.3K |
| Advance payment from customer | -$87.5K | $95.9K |
| Operating lease liabilities | -$34.5K | -$42.9K |
| Tax recoverable/(liabilities) | $22.8K | -$38.8K |
| Net cash used in operating activities | -$1.8M | -$2.1M |
| Acquisition of investments in equity securities | -$9.2K | -$492.7K |
| Dividend income | $22.1K | $68.1K |
| Change in fixed deposits placed with original maturities more than three months | -$62.9K | -$78.8K |
| Purchase of plant and equipment | -$37.0K | -$227.0K |
| Proceeds from disposal of investments in equity securities | $1.0M | $1.1M |
| Proceeds from settlement of supplier contract dispute | $0 | $79.9K |
| Net cash generated from investing activities | $944.8K | $418.2K |
| Advances from Directors | $32.3K | $4.0K |
| Cash paid for fractional shares in reverse stock split | -$775 | $0 |
| Share subscription | $267.3K | $0 |
| Net cash generated from financing activities | $298.8K | $4.0K |
| Foreign currency translation adjustment | $194.2K | $40.3K |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | -$400.6K | -$1.6M |
| Fixed deposits placed with financial institutions with original maturities of three months or less | $103.0K | $1.3M |
| Cash and bank balances | $2.4M | $1.6M |
| Cash and cash equivalents, end of financial year | $2.5M | $2.9M |
| Interest paid | -$6.9K | -$9.4K |
| Income tax refunded | $43.7K | $0 |
| Income tax paid | -$14.8K | -$40.4K |
| Acquisition of investment via share exchange | -$1.8M | $0 |
Former names
- BioNexus Gene Lab CoporationJan 29, 2019 to May 8, 20203
Recent filings
- Oct 7, 20268-K
- Aug 14, 202610-Q
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 2026SCHEDULE 13D
- Aug 7, 20263
- Jul 31, 20263
- Jul 31, 20263
- Jul 31, 20263
- Jul 31, 20263
- Jul 31, 20263
- Jul 28, 20268-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11